Search This Blog

Monday, October 28, 2019

CRISPR Therapeutics EPS beats by $3.33, beats on revenue

CRISPR Therapeutics (NASDAQ:CRSP): Q3 GAAP EPS of $2.40 beats by $3.33.
Revenue of $211.9M (+37739.3% Y/Y) beats by $128.21M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)